SUPER-1 is a 52-week (26-week main phase plus 26-week extension phase), phase 3, treat-to-target trial investigating the efficacy and safety of once-weekly GZR4 versus once-daily insulin glargine U100 ...
The FDA just approved Awiqli, a once-weekly insulin treatment for type 2 diabetes. Awiqli allows patients to shift from daily injections. The effectiveness, safety, and side effects are similar to ...
New international study findings demonstrated positive results of the first injectable glucagon-like peptide-1 receptor agonist (GLP-1 RA) and amylin analogue combination treatment in improving blood ...
Reducing injection burden has long been a priority in diabetes care. Now, a weekly, fixed-dose combination of basal insulin and a GLP-1 receptor agonist is one step closer to approval in Europe.
The MarketWatch News Department was not involved in the creation of this content. -- Awiqli(R) (insulin icodec-abae) injection is the first-ever once-weekly basal insulin approved by the FDA1 -- ...
Participants treated with retatrutide lost an average of 11.5% to 15.3% of their body weight, compared with only 2.6% among ...
Recent advances in insulin formulation have brought forth once-weekly therapies that promise improved adherence and consistent glycaemic control for people with diabetes. Traditional basal insulin ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Insulin efsitora was noninferior to once-daily insulins ...
PLAINSBORO, N.J., March 26, 2026 /PRNewswire/ -- Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Awiqli® (insulin icodec-abae) injection 700 units/mL, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results